Role of Endothelial Progenitor Cells Dysregulation and Inflammation in the Pathophysiology of Cardiovascular Complications of Type 2 Diabetes
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
- Кому может быть актуально
- Состояния в реестре: Diabete Type 2, Cardio Vascular Disease. Базовые параметры: от 18 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Катар
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Обзор
This study aims to isolate endothelial progenitor cells (EPCs) from participants with type 2 diabetes (T2D) and cardiovascular complications and to comprehensively characterize EPC dysfunction. Specifically, the study will evaluate maladaptive angiocrine signaling, calcium signaling pathways, and the role of inflammation in EPC function and the progression of atherosclerosis during T2D development. A sub-study will assess EPC functionality by examining endothelial nitric oxide synthase (eNOS) expression and activity, as well as the effectiveness of in vitro eNOS gene enhancement.
Подробное описание
Type 2 diabetes (T2D) is associated with damage to blood vessels, which can lead to serious complications such as heart disease, stroke, and other vascular problems.
Endothelial progenitor cells (EPCs) help maintain healthy blood vessels by repairing vascular injury. In people with T2D, the number and function of these cells are reduced, which may contribute to poor blood vessel repair and increased cardiovascular risk. The mechanisms responsible for this dysfunction are not fully understood. This study aims to examine how changes in cell signaling and chronic low-grade inflammation in T2D affect EPC function. EPCs will be isolated from patients with T2D, with and without cardiovascular complications, to assess their signaling properties, function, and ability to mature into vascular cells.
An in vitro sub-study will evaluate a potential therapeutic strategy to improve EPC function by increasing the activity of endothelial nitric oxide synthase (eNOS), a protein that plays a key role in maintaining healthy blood vessels. Reduced eNOS activity is an important contributor to vascular dysfunction in diabetes. Enhancing eNOS expression and function in EPCs may improve their regenerative capacity and help prevent or treat diabetic vascular complications.
Первичные конечные точки
- Characterization of EPCs dysregulation in Type 2 diabetes [Срок оценки: Following the EPC isolation (15 - 20 days).]
- Functional Analysis of inflammatory responses in Endothelial Progenitor Cells in type 2 Diabetes with cardiovascular complications [Срок оценки: Following the EPC isolation (15 - 20 days)]
Вторичные конечные точки (8)
- Expression levels of angiocrine factor genes in EPCs [Срок оценки: Following the EPC isolation (15-20 days)]
- Cytosolic calcium concetration in EPCs [Срок оценки: Following the EPC isolation (15-20 days)]
- Quantification of Mitochondrial reactive oxygen species (ROS) levels in EPCs [Срок оценки: Following the EPC isolation (15-20 days).]
- Protein Expression of Inflammatory Transcription Factors in Endothelial Progenitor Cells [Срок оценки: Following the EPC isolation (15 - 20 days).]
- Angiogenic Transcription Factor Expression in EPCs [Срок оценки: Time Frame: Following the EPC isolation (15 - 20 days).]
- Proportion of EPCs differentiating into endothelial cells in vitro [Срок оценки: 14 days after initiation of in vitro differentiation.]
- Measurement of eNOS(endothelial nitric oxide synthase)-Dependent Nitric Oxide Production in Endothelial Progenitor Cells [Срок оценки: Following EPC isolation (15-20 days) and 72 hours post-gene transfection.]
- Functional Outcomes of Genetically Enhanced Endothelial Progenitor Cells [Срок оценки: Following EPC isolation (15-20 days) and 72 hours post-gene transfection]
Критерии участия
Критерии включения
- T2D
- Males and females
- Older than 18 years of age
- Willingness to participate in the study and provide written consent form
- Consent to having peripheral blood withdrawals and urine collection for the study requirement.
Критерии исключения
- Unable to meet the inclusion criteria
- Type I diabetes, MODY diabetes or other form of diabetes
- Active infection, inflammation, cancer or acute illness of any kind (other than a cardiovascular complication of diabetes if applicable in the group they are assigned to).
- Chronic inflammation (eg. auto-immune diseases) or infections (eg. HIV, chronic hepatitis).
- Evidence of malignancy within the past 5 years
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Да
Дизайн исследования
- Модель наблюдения
- Когортное
Центры проведения
Катар · 1 центр
- Hamad Medical Corporation — Doha
Идентификаторы
NCT: NCT07556497 · 18-00008